NCT06177288View on ClinicalTrials.gov

DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases

NANot yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

May 1, 2025

Conditions
Colorectal Neoplasms
Interventions
COMBINATION_PRODUCT

DEBIRI Combined With Chemotherapy and Bevacizumab

After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.

Trial Locations (1)

200032

Zhongshan hospital, Fudan university, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06177288 - DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases | Biotech Hunter | Biotech Hunter